Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; Japan Science and Technology Corporation, Core Research for Evolutional Science and Technology, Gobancho, Chiyoda-ku, Tokyo, Japan.
Anat Rec (Hoboken). 2014 Jan;297(1):111-20. doi: 10.1002/ar.22804. Epub 2013 Dec 2.
Hematopoietic stem cells (HSCs) are defined by their capacity to self-renew and to differentiate into all blood cell lineages while retaining robust capacity to regenerate hematopoiesis. Based on these characteristics, they are widely used for transplantation and gene therapy. However, the dose of HSCs available for use in treatments is limited. Therefore, extensive work has been undertaken to expand HSCs in culture and to produce HSCs from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) in order to improve the efficiency and outcome of HSC-based therapies. Various surface markers have been characterized to improve the purification of HSCs and a huge number of cytokines and small-molecule compounds have been screened for use in the expansion of HSCs. In addition, attempts to generate not only HSCs but also mature blood cells from ESCs and iPSCs are currently ongoing. This review covers recent approaches for the purification, expansion or production of human HSCs and provides insight into problems that need to be resolved.
造血干细胞(HSCs)的定义特征是自我更新能力和向所有血细胞谱系分化的能力,同时保持强大的造血再生能力。基于这些特性,它们被广泛用于移植和基因治疗。然而,可用于治疗的 HSCs 剂量有限。因此,人们进行了广泛的工作来扩大 HSCs 的培养,并从胚胎干细胞(ESCs)和诱导多能干细胞(iPSCs)中产生 HSCs,以提高基于 HSC 的治疗的效率和结果。已经对各种表面标志物进行了表征,以改善 HSCs 的纯化,并且已经筛选了大量细胞因子和小分子化合物来扩大 HSCs 的扩增。此外,目前正在尝试不仅从 ESCs 和 iPSCs 中产生 HSCs,而且还产生成熟的血细胞。这篇综述涵盖了最近用于纯化、扩增或产生人类 HSCs 的方法,并深入探讨了需要解决的问题。